Dynamic International Prognostic Scoring System for Myelofibrosis

The Dynamic International Prognostic Scoring System predicts survival in myelofibrosis based on age, hemoglobin, leukocytosis, circulating blasts, and constitutional symptoms 1 [Level I evidence].

Age, years
≤ 650> 65+1
White blood cell count, x10^9/dL
≤ 250> 25+1
Hemoglobin, g/dL
≥ 100< 10+2
Peripheral blood blasts
< 1%0≥ 1%+1
Constitutional symptoms
No0Yes+1

使用適応

Used for primary or secondary myelofibrosis at any time during the disease course to dynamically stratify survival risk based on age, hemoglobin, leukocytes, blasts, and constitutional symptoms 1 [Level I evidence]. Guides transplant referral, intensity of therapy, and timing of JAK inhibitor or clinical‑trial consideration; higher scores predict inferior post‑transplant survival 2 [Level II evidence].

洞察と注意事項

Identifies survival risk using age >65, anemia, leukocytosis, blasts ≥1%, and constitutional symptoms, which dynamically worsen prognosis as factors are acquired 1 [Level I evidence]. High‑risk status strongly predicts inferior survival and post‑transplant mortality 2 [Level II evidence]. Use cautiously: lacks cytogenetics and molecular data, underestimates risk in adverse karyotype or high‑molecular‑risk mutations (e.g., ASXL1, SRSF2) incorporated later in DIPSS‑Plus 3 [Level I evidence].